MALARIA FALCIPARUM

This early-stage study tests whether giving the R21/Matrix-M malaria vaccine in a new, escalating-dose schedule is safe and creates a strong immune response. It involves 36 healthy adults in the UK who have never had malaria. The goal is to find a better way to protect people fro…

This study tests two experimental malaria vaccines in 360 children aged 5 to 36 months in Burkina Faso, a country where malaria is common. The vaccines aim to prevent malaria caused by the Plasmodium falciparum parasite. Researchers will check how safe the vaccines are, how well …

This study tests a new malaria vaccine called SUM-101 in 69 healthy children and infants aged 5 months to 5 years in Burkina Faso. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive three doses, and some infants also receive a ra…

This study tests whether screening pregnant women for malaria with a highly sensitive rapid test during the first trimester, followed by treatment if positive, can improve newborn health. Over 2,000 women in malaria-prone areas will be compared to those receiving usual care. The …

This study tests whether giving antimalarial drugs to entire communities can reduce malaria transmission. About 18,000 people in 50 villages in Senegal will take part. The goal is to clear hidden malaria parasites that standard treatments miss, especially during the dry season.

This study tests whether giving school children preventive malaria medicine can reduce infections not only in them but also in younger siblings at home. About 1,000 students in rural Malawi will receive either one of two drug combinations or no preventive treatment. Researchers w…

This study tracks how the malaria drug artemether-lumefantrine passes from a breastfeeding mother into her breastmilk and then into her nursing infant. Researchers will take blood and milk samples from 30 mother-infant pairs in Uganda over two weeks. The goal is to understand dru…